Accueil / Communiqués / OTC Markets Lists Securities of Fuse Medical, Inc. as Exempt from Penny Stock Designation

OTC Markets Lists Securities of Fuse Medical, Inc. as Exempt from Penny Stock Designation

Thursday, March 14th 2019 at 8:32pm UTC

RICHARDSON, Texas–(BUSINESS WIRE)– Fuse Medical, Inc., (OTC PINK: FZMD), (“Fuse” or the “Company”),
announced that OTC Markets has identified Fuse as “Penny Stock Exempt,”
meaning that shares of Fuse’s common stock, par value $0.01 per share
(the “Common Stock”), is no longer a “Penny Stock” as defined in
Rule 3a51-1, promulgated under the Securities Exchange Act of 1934, as
amended.

To qualify as “Penny Stock Exempt” on the OTC Markets, an issuer must
satisfy one of the following requirements: (i) the issuer’s securities
have a minimum price greater than $5 per share; (ii) the issuer has
average revenues of at least $6 million for the last three (3) years; or
(iii) the issuer has net tangible assets exceeding $2 million, if the
issuer has been in continuous operations for at least three (3) years or
$5 million if less than three (3) years.

“We are very pleased that OTC Markets has identified our Common Stock as
exempt from the Penny Stock designation on the OTC Pink markets,”
Christopher C. Reeg, Chief Executive Officer of Fuse, said. “With this
exemption, national broker/dealers may freely recommend our Common Stock
to their clients. We anticipate that this news may generate greater
interest in our Company.”

About Fuse Medical, Inc.

Fuse is a national distributor of medical devices, providing a broad
portfolio of internal and external fixation products; upper and lower
extremity plating and total joint reconstruction; soft tissue fixation
and augmentation for sports medicine procedures; full spinal implants
for trauma, degenerative disc disease, and deformity indications,
(collectively, “Orthopedic Implants”) and a wide array of
osteo-biologics, regenerative tissues, and amniotic tissue, which
include human allografts, substitute bone materials and tendons, and
regenerative tissues and fluids (“Biologics”). The Company’s
broad portfolio of Orthopedic Implants and Biologics provide
high-quality products to assist surgeons with positive patient outcomes
and cost-effective solutions for its customers. For more information
about Fuse, please visit:www.fusemedical.com.

Forward-Looking Statements

Certain statements in this press release, including those related to an
anticipated purchase of all of the outstanding membership units and
plans for the consolidated company, constitute “forward-looking
statements” within the meaning of the federal securities laws. Words
such as “may,” “might,” “will,” “should,” “believe,” “expect,”
“anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,”
“plan,” “intend,” or similar expressions or statements regarding intent,
belief, or current expectations, are forward-looking statements. While
the Company believes these forward-looking statements are reasonable,
undue reliance should not be placed on any such forward-looking
statements, which are based only on information available to the Company
as of the date of this release. These forward-looking statements are
based upon current estimates and assumptions and are subject to various
risks and uncertainties, including, without limitation, those set forth
in the Company’s filings with the Securities and Exchange Commission;
the failure of the Company to close the transaction; and integration
issues with the consolidated company. Thus, actual results could be
materially different. The Company expressly disclaims any obligation to
update or alter statements whether as a result of new information,
future events, or otherwise, except as required by law.

Contacts

Fuse Medical, Inc.
Attention: Devon Morgan, Investor
Relations Analyst

Office (469) 862-3030
Facsimile
(469) 862-3035

info@Fusemedical.com

Source: Fuse Medical, Inc.


Voir aussi

Innovations in Artificial Intelligence, Blockchain, Quantum Computing, Robots, and Catalysts, 2019 Study – ResearchAndMarkets.com

Friday, March 22nd 2019 at 3:01pm UTC DUBLIN–(BUSINESS WIRE)– The « Innovations in Artificial Intelligence, Blockchain, …